pharmaphorum

APRIL 19, 2022

RudaCure is a four-year-old biotech company based in the South Korea, focusing on ocular disease and chronic pain with a pair of potentially first-in-class drugs. The company recently raised $16.5 So] we are trying to go for the international market.”. “In The company’s second drug candidate, RCI002, is focused on chronic pain.

Marketing 52

Marketing Clinical Trials Clinical Trials Licensing 52

pharmaphorum

MAY 17, 2021

UK biotech Arecor Therapeutics has announced plans to float on the London stock market, to fund plans to develop novel formulations of insulins and other biological drugs with enhanced properties. Arecor has four active licensing agreement in place with partners including Hikma and Inhibrx.

Insulin 52

Insulin Production Marketing Pharma Companies 52

Pharmaceutical Technology

SEPTEMBER 2, 2022

In a recent report, GlobalData revealed that the US Food and Drug Administration (FDA) approved 122 new drug applications (NDAs) and biologic license applications (BLAs) in 2021. This is where partners such as Abacus Medicine Pharma Services can really help,” says Simon Estcourt, managing director of Abacus Medicine Pharma Services.

Drugs 130

Drugs Pharma Companies Sales Production 130

World of DTC Marketing

APRIL 12, 2021

QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. The goal of getting a drug to market as fast as possible so they can recoup drug development costs has the potential for mistakes that could cost lives. We can’t continue to develop drugs the same way as we have done before.

Generic Drugs 187

Generic Drugs Manufacturing Production Drugs 187

Drug Discovery World

APRIL 20, 2023

Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne , and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. developed dementia over the subsequent two years (vs. Notably, among over-65s who had had Covid-19, 4.5%

Development 98

Development Drugs Clinical Trials Clinical Trials 98

pharmaphorum

AUGUST 25, 2021

Jirair Ratevosian, executive director of global patient solutions and government affairs at Gilead Sciences, tells us how his company utilised previously developed partnerships and their knowledge of providing global access to HIV treatments to distribute Remdesivir. It’s not a coincidence that we now have over 2.3

Marketing 52

Marketing Licensing Licensing Manufacturing 52

Drug Discovery World

FEBRUARY 5, 2024

However, two-thirds (68%) of patients are comfortable receiving medicines before they’re licensed through their country’s healthcare system. The new data was released by pharma company Clinigen to mark the start of Rare Disease Month.

Medicine 52

Medicine Pharma Companies Licensing Licensing 52

pharmaphorum

JANUARY 8, 2021

There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth up to $960 million based around the anti-seizure drug cenobamate. It is already in the late stages of development and expected to be approved in Europe later this year.

Licensing 52

Licensing Licensing Pharma Companies Branding 52

pharmaphorum

JANUARY 20, 2022

The mission to treat people who suffer from allergic rhinitis has been given a boost as two pharma companies join forces. Ryaltris, which was developed by Glenmark, is a novel, fixed-dose combination nasal spray of an anti-histamine (olopatadine hydrochloride) and a steroid (mometasone furoate). with allergic rhinitis.

Allergies 72

Allergies Marketing Manufacturing Production 72

pharmaphorum

FEBRUARY 12, 2021

The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets around the world and had sales of around $140 million last year.

Drugs 111

Drugs Sales Pharma Companies Marketing 111

Camargo

SEPTEMBER 23, 2020

The panelists brought diverse perspectives on the future of orphan drug development, how their companies evaluate new potential products and partnering opportunities, and how they are working to address challenges like clinical study design and patient recruitment. Thomas Kassberg, Chief Business Officer, Ultragenyx.

Business Development 136

Business Development Drugs Development Production 136

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 96

Drugs Antibody Pharma Companies Development 96

Delveinsight

AUGUST 2, 2020

The dynamics of the cancer cachexia market is expected to gain momentum as several companies are testing the waters, advancing cancer cachexia pipeline. The company is currently preparing for further clinical trials in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC). Cancer Cachexia Pipeline.

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

SEPTEMBER 20, 2021

For the pharma industry, the pandemic’s changes were both abrupt and industry-altering, requiring companies to rapidly adapt their approaches to drug development and commercialisation. It also led to changes in how we manufacturer, market and ship medications. Personalisation is Key. Redefining Success Metrics.

Sales 97

Sales Marketing Pharma Companies Licensing 97

pharmaphorum

DECEMBER 6, 2022

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made by a top-tier pharma company – but in fact it comes from diminutive biotech Summit Therapeutics.

Licensing 52

Licensing Licensing Antibody Clinical Trials 52

pharmaphorum

JANUARY 6, 2022

The latest pharma company to make a move for an mRNA specialist is Germany’s Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. Exelead was part of that success, helping to manufacture vaccine precursors for the Pfizer/BioNTech shot Comirnaty.

Vaccination 98

Vaccination Vaccine Manufacturing Life Science 98

pharmaphorum

MAY 20, 2022

The new initiative – called ATOM (Access to Oncology Medicines) – pledges to tackle the issue that fewer than 50% of the cancer medicines on the World Health Organization’s essential medicines list are available in developing nations around the world. million in 2020 to 4 million by 2040, according to ATOM’s members. .”

Drugs 111

Drugs Medicine Licensing Licensing 111

pharmaphorum

FEBRUARY 13, 2022

German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

pharmaphorum

JUNE 4, 2021

At the moment, Xofigo is the only approved TAT on the market, but Bayer is also developing a pipeline of other candidates based on thorium-227 linked to antibodies or small-molecule drugs. The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 63

Antibody Licensing Licensing Protein 63

pharmaphorum

APRIL 22, 2021

In a filing with the Securities and Exchange Commission, Centessa said it plans to use proceeds to fund the development of the 16 drugs in its pipeline, as well as potential acquisitions. The company has an “asset focused” R&D philosophy , where development is centred on the needs of each individual biotech.

Licensing 54

Licensing Licensing Pharma Companies Drugs 54

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. ” She added that BioArctic will now “investigate options to continue the development of this asset.”

Antibody 93

Antibody Protein Gene Therapy Pharma Companies 93

pharmaphorum

JUNE 14, 2021

Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. This article appears in our free digital magazine Deep Dive: Market Access 2021.

Drugs 99

Drugs Pharma Companies Licensing Licensing 99

pharmaphorum

MARCH 8, 2022

Low-cost rivals to multiple myeloma therapy Revlimid (lenalidomide) started to become available in Europe earlier this year, and have now been introduced in the US market by Teva and Natco Pharma, under the terms of a license agreed with Revlimid’s original developer Celgene.

Sales 52

Sales Marketing Pharma Companies Licensing 52

Drug Discovery World

MAY 6, 2024

In this article, DDW’s Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany. respectively compared to an average market growth of 5.8%

Drugs 59

Drugs Life Science Gene Editing Gene 59

pharmaphorum

NOVEMBER 30, 2022

The biggest gathering of pharma companies in Europe right now on the commercial side, the Veeva Systems Summit permits the sharing of best practices and of new ideas. Facts that they gleaned included: Across Europe, only 52% of HCPs will accept a visit from a pharma company (i.e.

Life Science 98

Life Science Pharma Companies Sales Marketing 98

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

pharmaphorum

DECEMBER 16, 2022

Further, with a pandemic treaty in development, there are reasons to believe that many countries and the WHO want to see a more equitable distribution of medical products for future pandemics. The industry has so far resisted demands for the sharing of intellectual property (IP) around products developed to counter the pandemic.

Vaccination 90

Vaccination Vaccine Production Licensing 90

pharmaphorum

OCTOBER 28, 2020

Data defines modern therapeutics, but this is almost uniquely confined to the clinical trial stages of drug development. Identifying, recruiting, retaining and monitoring patients during this part of the cycle is estimated to cost pharma US$19 billion a year as companies seek to harvest patient experiences.

Medicine 119

Medicine Pharma Companies Vaccination Vaccine 119

pharmaphorum

SEPTEMBER 19, 2022

French pharma company Genfit has reached a deal to buy Versantis of Switzerland, adding three development-stage drug candidates to its portfolio of experimental liver disease therapies and continuing a strategy change first unveiled in 2020. Genfit thinks HE could be a $2 billion market opportunity.

Drugs 52

Drugs Development Pharma Companies Clinical Trials 52

pharmaphorum

FEBRUARY 15, 2022

billion in exercise fees and milestone payments, as well as tiered royalties should any of the ADCs reach the market. Lilly originally agreed paid $20 million upfront for a license to the maytansinoid technology in 2011, and expanded the partnership two years later, only to exit the agreement in 2018.

Antibody 52

Antibody Licensing Licensing Drugs 52

pharmaphorum

DECEMBER 9, 2022

The deal – which included a $50 million upfront payment and up to $450 million in follow-up payments – had advanced the RMC-4630 drug candidate from preclinical testing to a phase 2 trial in combination with Amgen’s first-to-market KRAS inhibitor Lumakras (sotorasib) as a treatment for KRASG12C mutated non-small cell lung cancer (NSCLC).

Pharma Companies 59

Pharma Companies Licensing Licensing Trials 59

pharmaphorum

NOVEMBER 15, 2022

This proved highly beneficial for those pitching products, mechanisms of action, and companies to investors, allowing them to focus on their presentations, instead of competing to cut through the chatter rising from the floor. How healthcare innovators are weathering market conditions.

Life Science 88

Life Science Pharma Companies Marketing Production 88

pharmaphorum

OCTOBER 7, 2021

The factory will be able to supply up to 500 million doses of mRNA shots a year, and cover the full spectrum of manufacturing from drug substance production through to full/finish and packaging, according to the company. According to the latest WHO data, just 4.4%

Vaccination 95

Vaccination Vaccine Manufacturing Packaging 95

pharmaphorum

JULY 5, 2021

Parexel has been a champion of the concept for years, but while adoption was fairly slow pre-COVID, it has accelerated at a fast pace since the crisis, aided by the increasing willingness of regulators to accept decentralised trial data in marketing applications.

Clinical Trials 64

Clinical Trials Clinical Trials Regulation Trials 64

Drug Discovery World

OCTOBER 16, 2023

Cambridge boasts the world-renowned university alongside a biotech and pharma cluster situated throughout the city and its surrounding science parks, all of which helps attract top scientific talent.” At ELRIG’s Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provided a snapshot of drug discovery in Scotland.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. As a result, there is a need for continued innovation and increased efficiency in terms of drug development to manage cost, complexity and speed to provide potentially transformative therapies for cancer patients.

Research 128

Research Gene Editing Gene Development 128

pharmaphorum

MAY 14, 2021

In an interview with pharmaphorum’s news editor Richard Staines, chief operating officer Arnout Ploos van Amstel revealed how the biotech and its “mystery CEO” managed to swoop for the drug ahead of big pharma rivals. Licensed in from Ablynx in 2013 five years before a merger with Sanofi, German Merck recognised its potential.

Licensing 60

Licensing Licensing Drugs Marketing 60